Get started
Author

Douglas Lundin

Observed name: D Lundin
OpenAlex ID: A5102140129
Moral hazard in physician prescription behavior
2000 · Douglas Lundin · Journal of Health Economics · 161
Why Did Drug Spending Increase During the 1990s?
2004 · Ulf-G Gerdtham, Douglas Lundin · PharmacoEconomics · 50
A median voter model of health insurance with ex post moral hazard
2004 · Johanna Jacob, Douglas Lundin · Journal of Health Economics · 48
On survival consumption costs – a reply to Nyman
2007 · Douglas Lundin, Joakim Ramsberg · Health Economics · 24
Antidepressants and the Suicide Rate: Is There Really a Connection?
2005 · Matz Dahlberg, Douglas Lundin · RePEc: Research Papers in Economics · 19
Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden
2004 · Joakim Ramsberg, Stefan Odeberg, et al. · The European Journal of Health Economics · 18
Antidepressants and the suicide rate: is there really a connection?
2006 · Matz Dahlberg, Douglas Lundin · Advances in health economics and health services research · 15
Dynamic Cost-Effectiveness: A More Efficient Reimbursement Criterion
2008 · Douglas Lundin, Joakim Ramsberg · Forum for Health Economics & Policy · 10
The ageing of society, health services provision and taxes
2005 · Ulf-G. Gerdtham, Douglas Lundin, et al. · Journal of Population Economics · 10
Implementing a sandbox approach in health technology assessment: benefits and recommendations
2024 · Jamie Elvidge, Nick Crabb, et al. · International Journal of Technology Assessment in Health Care · 9
PDF
Welfare-Improving Carbon Dioxide Tax Reform Taking Externality and Location into Account
2001 · Douglas Lundin · International Tax and Public Finance · 9
The Impact of Physician Preferences and Patient Habits on the Diffusion of New Drugs
2002 · Magnus Johannesson, Douglas Lundin · RePEc: Research Papers in Economics · 6
PDF
Changes in drug spending for different age groups during the 1990s? Evidence from Sweden
2004 · Ulf-G Gerdtham, Douglas Lundin · Expert Review of Pharmacoeconomics & Outcomes Research · 5
Validation of overall survival extrapolations made by TLV in the assessment of cost-effectiveness of oncology drugs in Sweden – A pilot study comparing extrapolated and observed life-years gained
2024 · Jonas Björnerstedt, Hannah Almqvist, et al. · Journal of Medical Economics · 2
Incentives for clinical trials
2009 · Erik Grönqvist, Douglas Lundin · Economics of Innovation and New Technology · 2
[The generics reform lowered drug prices].
2007 · Douglas Lundin, Johanna Jacob, et al. · PubMed · 1
Php37 Generic Competition: Effect on Prices and Substitution Effects
2006 · A Engstrom, D Lundin, et al. · Value in Health · 1
PDF
Intergenerational Redistribution, Health Care, and Politics
2002 · Douglas Lundin, María Sáez Martí · RePEc: Research Papers in Economics · 1
PDF
Studies in empirical public economics
1999 · Douglas Lundin · 1
HTA285 Spillover Effects Among Significant Others When Making Decision Regarding Reimbursement of Pharmaceuticals in the Swedish Context
2024 · K Degerlund Maldi, A Sharma, et al. · Value in Health
PDF
HTA159 Approaches to Consider Spillover Effects Among Significant Others in Decisions About Health Care Interventions
2024 · A Lind, K Degerlund Maldi, et al. · Value in Health
[Reply from TLV on priorities: You do not deserve less care or medications just because you do not work].
2013 · Douglas Lundin, Leif Lundquist · PubMed
[Guidelines of the Pharmaceutical Benefits Board for health economics evaluations. Cost-efficiency analysis from a national perspective].
2006 · Douglas Lundin, Per Carlsson, et al. · PubMed
Incentives for Clinical Trials
2006 · Erik Grönqvist, Douglas Lundin · RePEc: Research Papers in Economics
[Why patent-protected drugs' cost efficiency should be compared with generic preparations].
2006 · Fredrik Berggren, Douglas Lundin, et al. · PubMed
Works count: 29
Citation count: 392
H-index: 9
I10-index: 9
Year
Topic
Type